摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-(3-chloro-phenylethynyl)-4H-benzo[1,4]oxazin-3-one | 528892-42-4

中文名称
——
中文别名
——
英文名称
6-(3-chloro-phenylethynyl)-4H-benzo[1,4]oxazin-3-one
英文别名
6-[2-(3-chlorophenyl)ethynyl]-4H-1,4-benzoxazin-3-one
6-(3-chloro-phenylethynyl)-4H-benzo[1,4]oxazin-3-one化学式
CAS
528892-42-4
化学式
C16H10ClNO2
mdl
——
分子量
283.714
InChiKey
REQJSWUQLRXTRA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.5
  • 重原子数:
    20
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.06
  • 拓扑面积:
    38.3
  • 氢给体数:
    1
  • 氢受体数:
    2

文献信息

  • Phenyl substituted triazoles and their use as selective inhibitors of akl5 kinase
    申请人:Gaster Mary Laramie
    公开号:US20050014938A1
    公开(公告)日:2005-01-20
    Phenyl substituted triazoles of formula (I) wherein R 1 is naphthyl or phenyl optionally substituted with one or more substituents selected from halo, —O—C 1-6 alkyl, —S—C 1-6 alkyl, C 1-6 alkyl, C 1-6 haloalkyl, —O—(CH 2 ) n -Ph, —S—(CH 2 ) n -Ph, cyano, phenyl, and CO 2 R, wherein R is hydrogen or C 1-6 alkyl, and n is 0, 1, 2 or 3; or R 1 is phenyl or pyridyl fused with an aromatic or non-aromatic cyclic ring of 5-7 members wherein said cyclic ring optionally contains up to three heteroatoms, independently selected from N, O and S, and N may be further optionally substituted by C 1-6 alkyl, and wherein the cyclic ring may be optionally substituted by ═O; R 2 and R 3 are independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, phenyl, NH(CH 2 ) n -Ph, NH—C 1-6 alkyl, halo, alkoxy, CN, NO 2 , CONHR and SO 2 NHR; two of X 1 , X 2 and X 3 are N and the other is NR 4 wherein R 4 is hydrogen, C 1-6 alkyl, C 3-7 cycloalkyl, —(CH 2 ) p —CN, —(CH 2 ) p —CO 2 H, —(CH 2 ) p —CONHR 5 R 6 , —(CH 2 ) p COR 5 , —(CH 2 ) q (CR 7 ) 2 , —(CH 2 ) p OR 5 , (CH 2 ) q CH═CH—CN, —(CH 2 ) q —CH═CH—CO 2 H, —(CH 2 ) p —CH═CH—CONHR 5 R 6 , —(CH 2 ) p NHCOR 8 or —(CH 2 ) p NR 9 R 10 ; R 5 and R 6 are independently hydrogen or C 1-6 alkyl; R 7 is C 1-6 alkyl; R 8 is C 1-7 alkyl, or optionally substituted aryl, heteroaryl, arylC 1-6 alkyl or heteroaryl C 1-6 alkyl; R 9 and R 10 are independently selected from hydrogen, C 1-6 alkyl, aryl and arylC 1-6 alkyl; p is 0-4; and q is 1-4 and salts and solvates thereof, are disclosed, as are methods for their preparation, pharmaceutical compositions containing them and their use in medicine.
    式(I)的苯基取代三唑 其中 R 1 是基或苯基,可任选被一个或多个取代基取代,这些取代基选自卤、-O-C 1-6 烷基、-S-C 1-6 烷基、C 1-6 烷基,C 1-6 卤代烷基、-O-(CH 2 ) n -Ph,-S-(CH 2 ) n -Ph、基、苯基和 CO 2 R,其中 R 是氢或 C 1-6 烷基,且 n 为 0、1、2 或 3;或 R 1 是苯基或吡啶基,与由 5-7 个成员组成的芳香族或非芳香族环合并,其中所述环可任选包含最多三个杂原子,这些杂原子独立地选自 N、O 和 S,且 N 可进一步任选被 C 1-6 烷基取代。 1-6 烷基取代,其中环环可任选被 ═O 取代; R 2 和 R 3 独立选自 H、C 1-6 烷基、C 1-6 烷氧基、苯基、NH(CH 2 ) n -苯基、NH-C 1-6 烷基、卤代、烷氧基、CN、NO 2 、CONHR 和 SO 2 NHR; X 的两个 1 , X 2 和 X 3 是 N,另一个是 NR 4 其中 R 4 是氢、C 1-6 烷基 3-7 环烷基、-(CH 2 ) p -CN,-(CH 2 ) p -CO 2 H, -(CH 2 ) p -CONHR 5 R 6 ,-(CH 2 ) p COR 5 ,-(CH 2 ) q (CR 7 ) 2 ,-(CH 2 ) p 或 5 , (CH 2 ) q CH═CH-CN, -(CH 2 ) q 2 ) q -CH═CH-CO 2 H, -(CH 2 ) p -CH═CH-CONHR 5 R 6 ,-(CH 2 ) p NHCOR 8 或-(CH 2 ) p NR 9 R 10 ; R 5 和 R 6 独立地为氢或 C 1-6 烷基; R 7 是 C 1-6 烷基; R 8 是 C 1-7 烷基,或任选取代的芳基、杂芳基、芳基C 1-6 烷基或杂芳基 C 1-6 烷基; R 9 和 R 10 独立选自氢、C 1-6 烷基、芳基和芳基C 1-6 烷基;p 为 0-4;q 为 1-4,并公开了它们的盐和溶剂,以及它们的制备方法、含有它们的药物组合物和它们在医学中的用途。
  • Benzoxazine and benzoxazinone substituted triazoles
    申请人:Gellibert Jeanne Francoise
    公开号:US20050165011A1
    公开(公告)日:2005-07-28
    This invention relates to benzoxazine and benzoxazinone substituted triazoles which are inhibitors of the transforming growth factor, (“TGF”)-β signalling pathway, in particular, the phosphorylation of smad2 or smad3 by the TGF-β, type I or activin-like kinase (“ALK”)-5 receptor, methods for their preparation and their use in medicine, specifically in the treatment and prevention of a disease state mediated by this pathway.
    本发明涉及苯并噁嗪和苯并噁嗪酮取代的三唑类化合物,它们是转化生长因子("TGF")-β 信号通路的抑制剂,特别是 TGF-β、I 型或类活化因子激酶("ALK")-5 受体对 smad2 或 smad3 磷酸化的抑制剂,本发明还涉及它们的制备方法及其在医学中的用途,特别是在治疗和预防由该通路介导的疾病中的用途。
  • PHENYL SUBSTITUTED TRIAZOLES AND THEIR USE AS SELECTIVE INHIBORS OF AKL5 KINASE
    申请人:SMITHKLINE BEECHAM CORPORATION
    公开号:EP1444232A1
    公开(公告)日:2004-08-11
  • [EN] PHENYL SUBSTITUTED TRIAZOLES AND THEIR USE AS SELECTIVE INHIBORS OF AKL5 KINASE<br/>[FR] TRIAZOLES A SUBSTITUTION PHENYLE ET LEUR UTILISATION EN TANT QU'INHIBITEURS SELECTIFS DE LA KINASE ALK5
    申请人:SMITHKLINE BEECHAM CORP
    公开号:WO2003042211A1
    公开(公告)日:2003-05-22
    Phenyl substituted triazoles of formula (I) wherein R1 is naphthyl or phenyl optionally substituted with one or more substituents selected from halo, -O-C1-6alkyl, -S-C1-6alkyl, C1-6alkyl, C1-6haloalkyl, -O-(CH2)n-Ph, -S-(CH2)n-Ph, cyano, phenyl, and CO2R, wherein R is hydrogen or C1-6alkyl, and n is 0, 1, 2 or 3; or R1 is phenyl or pyridyl fused with an aromatic or non-aromatic cyclic ring of 5-7 members wherein said cyclic ring optionally contains up to three heteroatoms, independently selected from N, O and S, and N may be further optionally substituted by C1-6 alkyl, and wherein the cyclic ring may be optionally substituted by =O; R2 and R3 are independently selected from H, C1-6alkyl, C1-6alkoxy, phenyl, NH(CH2)n-Ph, NH-C1-6alkyl, halo, alkoxy, CN, NO2, CONHR and SO2NHR; two of X1, X2 and X3 are N and the other is NR4 wherein R4 is hydrogen, C1-6alkyl, C3-7cycloalkyl, -(CH2)p-CN, -(CH2)p-CO2H, -(CH2)p-CONHR5R6, -(CH2)pCOR5, -(CH2)q(OR7)2, -(CH2)pOR5, -(CH2)q-CH=CH-CN, -(CH2)q-CH=CH-CO2H, -(CH2)p-CH=CH-CONHR5R6, -(CH2)pNHCOR8 or -(CH2)pNR9R10; R5 and R6 are independently hydrogen or C1-6alkyl; R7 is C1-6alkyl;R8 is C1-7alkyl, or optionally substituted aryl, heteroaryl, arylC1-6alkyl or heteroaryl C1-6alkyl; R9 and R10 are independently selected from hydrogen, C1-6alkyl, aryl and arylC1-6alkyl; p is 0-4; and q is 1-4 and salts and solvates thereof, are disclosed, as are methods for their preparation, pharmaceutical compositions containing them and their use in medicine.
查看更多

同类化合物

()-2-(5-甲基-2-氧代苯并呋喃-3(2)-亚乙基)乙酸乙酯 (双(2,2,2-三氯乙基)) (乙基N-(1H-吲唑-3-基羰基)ethanehydrazonoate) (Z)-3-[[[2,4-二甲基-3-(乙氧羰基)吡咯-5-基]亚甲基]吲哚-2--2- (S)-(-)-5'-苄氧基苯基卡维地洛 (S)-(-)-2-(α-(叔丁基)甲胺)-1H-苯并咪唑 (S)-(-)-2-(α-甲基甲胺)-1H-苯并咪唑 (S)-氨氯地平-d4 (S)-8-氟苯并二氢吡喃-4-胺 (S)-4-(叔丁基)-2-(喹啉-2-基)-4,5-二氢噁唑 (S)-4-氯-1,2-环氧丁烷 (S)-3-(2-(二氟甲基)吡啶-4-基)-7-氟-3-(3-(嘧啶-5-基)苯基)-3H-异吲哚-1-胺 (S)-2-(环丁基氨基)-N-(3-(3,4-二氢异喹啉-2(1H)-基)-2-羟丙基)异烟酰胺 (SP-4-1)-二氯双(喹啉)-钯 (SP-4-1)-二氯双(1-苯基-1H-咪唑-κN3)-钯 (R,S)-可替宁N-氧化物-甲基-d3 (R,S)-六氢-3H-1,2,3-苯并噻唑-2,2-二氧化物-3-羧酸叔丁酯 (R)-(+)-5'-苄氧基卡维地洛 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-卡洛芬 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (R)-4-异丙基-2-恶唑烷硫酮 (R)-3-甲基哌啶盐酸盐; (R)-2-苄基哌啶-1-羧酸叔丁酯 (N-(Boc)-2-吲哚基)二甲基硅烷醇钠 (N-{4-[(6-溴-2-氧代-1,3-苯并恶唑-3(2H)-基)磺酰基]苯基}乙酰胺) (E)-2-氰基-3-(5-(2-辛基-7-(4-(对甲苯基)-1,2,3,3a,4,8b-六氢环戊[b]吲哚-7-基)-2H-苯并[d][1,2,3]三唑-4-基)噻吩-2-基)丙烯酸 (E)-2-氰基-3-[5-(2,5-二氯苯基)呋喃-2-基]-N-喹啉-8-基丙-2-烯酰胺 (8α,9S)-(+)-9-氨基-七氢呋喃-6''-醇,值90% (6R,7R)-7-苯基乙酰胺基-3-[(Z)-2-(4-甲基噻唑-5-基)乙烯基]-3-头孢唑啉-4-羧酸二苯甲基酯 (6-羟基嘧啶-4-基)乙酸 (6,7-二甲氧基-4-(3,4,5-三甲氧基苯基)喹啉) (6,6-二甲基-3-(甲硫基)-1,6-二氢-1,2,4-三嗪-5(2H)-硫酮) (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5R,Z)-3-(羟基((1R,2S,6S,8aS)-1,3,6-三甲基-2-((E)-prop-1-en-1-yl)-1,2,4a,5,6,7,8,8a-八氢萘-1-基)亚甲基)-5-(羟甲基)-1-甲基吡咯烷-2,4-二酮 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-(4-乙氧基-3-甲基苄基)-1,3-苯并二恶茂) (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氯-2,1,3-苯并噻二唑-4-基)-氨基甲氨基硫代甲酸甲酯一氢碘 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (5-氨基-1,3,4-噻二唑-2-基)甲醇 (4aS-反式)-八氢-1H-吡咯并[3,4-b]吡啶 (4aS,9bR)-6-溴-2,3,4,4a,5,9b-六氢-1H-吡啶并[4,3-B]吲哚 (4S,4''S)-2,2''-环亚丙基双[4-叔丁基-4,5-二氢恶唑] (4-(4-氯苯基)硫代)-10-甲基-7H-benzimidazo(2,1-A)奔驰(德)isoquinolin-7一 (4-苄基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4-甲基环戊-1-烯-1-基)(吗啉-4-基)甲酮 (4-己基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4,5-二甲氧基-1,2,3,6-四氢哒嗪)